At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 211 enrolled
Drug / intervention
Nivolumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 3b/4 Safety Trial of Nivolumab Combined With Ipilimumab in Subjects With Previously Untreated, Advanced or Metastatic RCC (CheckMate 920: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 920)
In Brief
A Phase 4 clinical trial evaluating Nivolumab and Ipilimumab for Renal Cell Carcinoma. Completed, enrolled 211 participants across 61 sites.
Detailed Summary
To investigate the safety of Nivolumab in combination with Ipilimumab in subjects with previously untreated advanced or metastatic Renal Cell Cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRenal Cell Carcinoma
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
2017201820192020202120222023202420252026
First PostedDec 2016
Enrollment StartJan 2017
Primary CompletionMay 2020
Study CompletionOct 2021
TodayJul 2026
First PostedDec 6, 2016
Enrollment StartJan 16, 2017
Primary CompletionMay 11, 2020
Study CompletionOct 6, 2021
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 9.6 years ago
Interventions
Nivolumabdrug
Specified dose on specified day
Ipilimumabdrug
Specified Dose on Specified Day